

AG  
can't

IgG2a mAb directed against sheep red blood cells. S-S.1 was produced using a commercially available cell line that makes the antibody (ATCC Accession No. TIB-111) and is being used as an irrelevant isotype-matched control antibody. ~~un~~

**In the Claims:**

Please cancel <sup>✓</sup>claims 34-46<sup>✓</sup>, without prejudice to including the subject matter of these claims in one or more other patent applications.

Please amend claims 2, 3, 9, 12, and 22 to read as follows:

Sub B1  
A7  
2. (Amended) The method of claim 1, wherein the anti-CD18 antibody binds specifically with the CD18 portion of the protein, but does not bind specifically with the non-CD18 portion of the protein.

3. (Amended) The method of claim 1, wherein the anti-CD18 antibody is a competitive inhibitor of the binding of monoclonal antibody 1B4 to human CD18.

AG  
9. (Amended) The method of claim 6, wherein binding of the anti-CD18 antibody with the antigen inhibits binding of a known ligand of the antigen with the CD18 portion of the protein.

AG  
12. (Amended) The method of claim 1, wherein binding of the anti-CD18 antibody with the CD18 portion of the protein modulates at least one function normally associated with binding of a natural ligand of the protein therewith.

A10  
22. (Amended) The method of claim 21, wherein the antibody fragment is selected from the group consisting of Fv, Fab, Fab', and F(ab')<sub>2</sub> fragments.